182 related articles for article (PubMed ID: 34714843)
1. A novel paclitaxel coated balloon with increased drug transfer for treatment of complex vascular lesions.
Gemeinhardt O; Schnorr B; Speck U; Scheller B
PLoS One; 2021; 16(10):e0259106. PubMed ID: 34714843
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
[No Abstract] [Full Text] [Related]
3. Pharmacokinetic Evaluation of Two Paclitaxel-Coated Balloons with Different Drug Load in a Short-Term Porcine Study.
Abadal JM; Vazquez E; Morales M; Toro A; Quintana M; Araujo M
Cardiovasc Intervent Radiol; 2016 Aug; 39(8):1152-8. PubMed ID: 27094691
[TBL] [Abstract][Full Text] [Related]
4. Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon: The ILLUMENATE European Randomized Clinical Trial 2-Year Results.
Brodmann M; Werner M; Meyer DR; Reimer P; Krüger K; Granada JF; Jaff MR; Schroeder H;
JACC Cardiovasc Interv; 2018 Dec; 11(23):2357-2364. PubMed ID: 30522663
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-coated versus plain old balloon angioplasty for the treatment of infrainguinal arterial disease in diabetic patients: the Belgian diabetic IN.PACT Trial.
Debing E; Aerden D; Vanhulle A; Gallala S; von Kemp K;
J Cardiovasc Surg (Torino); 2017 Aug; 58(4):528-534. PubMed ID: 27727202
[TBL] [Abstract][Full Text] [Related]
6. Improvement of Outcome for Treatment of 'Restenosis-prone' Vascular Lesions? Potential Impact of the Paclitaxel dose on Late Lumen Loss in Porcine Peripheral Arteries.
Gemeinhardt O; Haase T; Schnorr B; Xie J; Löchel M; Schütt D; Mittag A; Haider W; Bettink S; Speck U; Tepe G
Cardiovasc Intervent Radiol; 2022 Dec; 45(12):1822-1831. PubMed ID: 36109387
[TBL] [Abstract][Full Text] [Related]
7. Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study.
Zeller T; Langhoff R; Rocha-Singh KJ; Jaff MR; Blessing E; Amann-Vesti B; Krzanowski M; Peeters P; Scheinert D; Torsello G; Sixt S; Tepe G;
Circ Cardiovasc Interv; 2017 Sep; 10(9):e004848. PubMed ID: 28916599
[TBL] [Abstract][Full Text] [Related]
8. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
[TBL] [Abstract][Full Text] [Related]
9. Safety of Zilver PTX Drug-Eluting Stent Implantation Following Drug-Coated Balloon Dilation in a Healthy Swine Model.
Torii S; Yahagi K; Mori H; Harari E; Romero ME; Kolodgie FD; Young B; Ragheb A; Virmani R; Finn AV
J Endovasc Ther; 2018 Feb; 25(1):118-126. PubMed ID: 29161933
[TBL] [Abstract][Full Text] [Related]
10. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
[TBL] [Abstract][Full Text] [Related]
11. Novel, vessel anatomy adjusting drug-coated balloon-Preclinical evaluation in peripheral porcine arteries.
Bienek S; Kusmierczuk M; Mittag A; Bettink S; Scheller B
Catheter Cardiovasc Interv; 2020 Feb; 95(2):319-328. PubMed ID: 31696642
[TBL] [Abstract][Full Text] [Related]
12. Provisional Stenting Using the Zilver PTX Drug-Eluting Stent After Drug-Coated Balloon Angioplasty: Initial Experience From the Double Drug Dose "3D" Study.
Fanelli F; Cannavale A; Citone M; Santoni M; Gazzetti M; Falcone GM; Miele V
J Endovasc Ther; 2020 Feb; 27(1):34-41. PubMed ID: 31637956
[No Abstract] [Full Text] [Related]
13. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
[TBL] [Abstract][Full Text] [Related]
14. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
[TBL] [Abstract][Full Text] [Related]
15. Turbo-Power™ Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis.
Giannopoulos S; Kokkinidis DG; Jawaid O; Behan S; Hossain P; Alvandi B; Foley TR; Singh GD; Waldo SW; Armstrong EJ
Cardiovasc Revasc Med; 2020 Jun; 21(6):771-778. PubMed ID: 31761634
[TBL] [Abstract][Full Text] [Related]
16. Development of drug-coated balloon for the treatment of multiple peripheral artery segments.
Anderson JA; Lamichhane S; Fuglsby K; Remund T; Pohlson K; Evans R; Engebretson D; Kelly P
J Vasc Surg; 2020 May; 71(5):1750-1757.e7. PubMed ID: 31519510
[TBL] [Abstract][Full Text] [Related]
17. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
Bausback Y; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
J Endovasc Ther; 2017 Aug; 24(4):459-467. PubMed ID: 28558502
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
Caradu C; Lakhlifi E; Colacchio EC; Midy D; Bérard X; Poirier M; Ducasse E
J Vasc Surg; 2019 Sep; 70(3):981-995.e10. PubMed ID: 31126769
[TBL] [Abstract][Full Text] [Related]
19. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
Steiner S; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
JACC Cardiovasc Interv; 2018 May; 11(10):934-941. PubMed ID: 29730375
[TBL] [Abstract][Full Text] [Related]
20. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Isolated Popliteal Artery Lesions.
Stavroulakis K; Schwindt A; Torsello G; Stachmann A; Hericks C; Bosiers MJ; Beropoulis E; Stahlhoff S; Bisdas T
J Endovasc Ther; 2017 Apr; 24(2):181-188. PubMed ID: 28008792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
